Bioleaders Corporation (142760) Stock Overview

Bioleaders Corporation engages in the medicine and consumer business in South Korea. The company offers P53, a target anti-cancer drug. Its pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment vaccine of cervical cancer; BLC-H03, an H. vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 for the treatment of Duchenne muscular dystrophy. The company also provides health functional foods and raw materials, and cosmetical raw materials. Bioleaders Corporation was founded in 1999 and is headquartered in Yongin-si, South Korea.